<DOC>
	<DOCNO>NCT00288223</DOCNO>
	<brief_summary>Study objective : - document clinical efficacy telithromycin ( 800 mg per day 5 day ) Test Of Cure ( TOC ) visit ( D12-D19 ) , acute exacerbation chronic bronchitis . - assess long-term clinical efficacy telithromycin telephone D25-D35 ( V3 ) - ass safety telithromycin</brief_summary>
	<brief_title>Telithromycin Acute Exacerbation Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Outpatients , With documented history chronic bronchitis define one expectoration daily least three consecutive month least two consecutive year Presenting evident acute exacerbation disease define presence least two Anthonisen 's criterion : exacerbation dyspnea , increase expectoration volume , increase expectoration purulence , Acute bronchitis , Chronic obstructive pulmonary disease , FEV1 value &lt; 35 % ( FEV1 : Forced Expiratory Volume 1 second ) Suspected pneumonia bronchial pneumonia , Paroxysmal asthma continuous dyspnea asthma , Cystic fibrosis , Active tuberculosis , Lung cancer lung metastasis , Severe bronchiectasia , Acute respiratory decompensation , Chronic respiratory insufficiency associate rest hypoxemia , Patients require hospitalization parenteral antibiotic treatment Patients suspect known bacterial infection study disease , well associate systemic intratracheal antibiotic treatment study treatment , Participating another clinical study product within 30 day inclusion study Known immunosuppression ( AIDS and/or CD4+ lymphocytes &lt; 200/mm3 , neutropenia &lt; 1500/mm3 , blood disease terminal stage cancer ) Cardiovasculary , neurologic severe disease interfere compliance study protocol confusing result . Conditions associate study medication : Hypersensitivity telithromycin , macrolides excipients , Congenital long QT syndrome family history congenital long QT syndrome ( possibility exclude normal ECG ) know acquire QT interval prolongation , Treatment CYP3A4 inducer ( rifampicin , carbamazepine , phenytoin , phenobarbital , StJohn'swort ) within 2 week prior study inclusion Possibility treatment ergot alkaloid derivative , terfenadine , astemizole , pimozide , cisapride , simvastatin , athorvastatin lovastatin study Congenital galactosemia , lactase deficiency glucose galactose malabsorption syndrome , Pregnant lactate woman , Women childbearing potential ( e.g . ovulating , premenopausal surgically sterilize ) employ effective contraception method The patient may participate study . The patient treat study drug previously may participate study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>